bullish
Opdivo Potential Capped Due to Pricing Pressure and Keytruda Competition
403 Views17 Jul 2018 22:28
We reiterate our “Equal-weight” rating on the stock after reviewing our model post FY17 (YE Mar-18) earningsKey HighlightsBrisk Opdivo royalty...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 8-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Ono 1H FY18 (YE Mar'19) Results - First Glance01 Nov 2018
- Opdivo Potential Capped Due to Pricing Pressure and Keytruda Competition17 Jul 2018
- Ono FY17 Earnings - First Glance11 May 2018
- Ono’s Stock Price Decline on Merck’s KN-189 Success18 Apr 2018
- Ono’s Stock Price Decline on Merck’s KN-042 Success12 Apr 2018
x